K A Young1, M E Munroe2, J M Guthridge2, D L Kamen3, G S Gilkensen3, J B Harley4,5, M H Weisman6, D R Karp7, D J Wallace6, J A James2,8, J M Norris1. 1. 1 Department of Epidemiology, Colorado School of Public Health, Aurora, United States of America. 2. 2 Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America. 3. 3 Division of Rheumatology, Medical University of South Carolina, Charleston, United States of America. 4. 4 Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, United States of America. 5. 5 US Department of Veterans Affairs Medical Center, Cincinnati, United States of America. 6. 6 Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, United States of America. 7. 7 Division of Rheumatic Diseases, University of Texas Southwestern, Dallas, United States of America. 8. 8 Departments of Medicine and Pathology, Oklahoma University Health Sciences Center, Oklahoma City, United States of America.
Abstract
OBJECTIVE: Further prospective study is needed to elucidate the etiology and natural history of systemic lupus erythematosus development. The clinical complexity of this heterogeneous disease makes study design challenging. Our objective was to ascertain useful screening factors for identifying at-risk individuals for follow-up rheumatologic assessment or inclusion in prospective studies. METHODS: We attempted to re-contact 3823 subjects with a family history of systemic lupus erythematosus, who did not meet American College of Rheumatology systemic lupus erythematosus classification at a baseline study visit; 436 agreed to follow-up participation an average of 6.3 years after baseline. In total, 56 of these individuals had transitioned to classified systemic lupus erythematosus (≥ 4 cumulative American College of Rheumatology criteria, verified by medical record review) by the time of follow up. Generalized estimating equations assessed associations between our dichotomous outcome of transitioning to systemic lupus erythematosus with baseline characteristics, including ANA positivity, Connective Tissue Disease Screening questionnaire systemic lupus erythematosus score, and number of American College of Rheumatology criteria. We analyzed predictive accuracy of characteristics on transitioning. RESULTS: ANA positivity, Connective Tissue Disease Screening questionnaire systemic lupus erythematosus score categorization of possible or probable systemic lupus erythematosus, and greater number of American College of Rheumatology criteria at baseline were each associated with transitioning to systemic lupus erythematosus classification. Being ANA positive and having confirmed immunologic criteria at baseline had the highest positive predictive value and specificity for transitioning to systemic lupus erythematosus. American College of Rheumatology Connective Tissue Disease Screening questionnaire systemic lupus erythematosus score categorization of possible or probable systemic lupus erythematosus had a better positive predictive value, negative predictive value, sensitivity, and specificity than ANA positivity. CONCLUSION: Given limited resources, identifying individuals for follow up based on the systemic lupus erythematosus portion of the Connective Tissue Disease Screening questionnaire could be an efficient way to identify family members at highest risk of disease transition.
OBJECTIVE: Further prospective study is needed to elucidate the etiology and natural history of systemic lupus erythematosus development. The clinical complexity of this heterogeneous disease makes study design challenging. Our objective was to ascertain useful screening factors for identifying at-risk individuals for follow-up rheumatologic assessment or inclusion in prospective studies. METHODS: We attempted to re-contact 3823 subjects with a family history of systemic lupus erythematosus, who did not meet American College of Rheumatology systemic lupus erythematosus classification at a baseline study visit; 436 agreed to follow-up participation an average of 6.3 years after baseline. In total, 56 of these individuals had transitioned to classified systemic lupus erythematosus (≥ 4 cumulative American College of Rheumatology criteria, verified by medical record review) by the time of follow up. Generalized estimating equations assessed associations between our dichotomous outcome of transitioning to systemic lupus erythematosus with baseline characteristics, including ANA positivity, Connective Tissue Disease Screening questionnaire systemic lupus erythematosus score, and number of American College of Rheumatology criteria. We analyzed predictive accuracy of characteristics on transitioning. RESULTS: ANA positivity, Connective Tissue Disease Screening questionnaire systemic lupus erythematosus score categorization of possible or probable systemic lupus erythematosus, and greater number of American College of Rheumatology criteria at baseline were each associated with transitioning to systemic lupus erythematosus classification. Being ANA positive and having confirmed immunologic criteria at baseline had the highest positive predictive value and specificity for transitioning to systemic lupus erythematosus. American College of Rheumatology Connective Tissue Disease Screening questionnaire systemic lupus erythematosus score categorization of possible or probable systemic lupus erythematosus had a better positive predictive value, negative predictive value, sensitivity, and specificity than ANA positivity. CONCLUSION: Given limited resources, identifying individuals for follow up based on the systemic lupus erythematosus portion of the Connective Tissue Disease Screening questionnaire could be an efficient way to identify family members at highest risk of disease transition.
Entities:
Keywords:
Family studies; screening; systemic lupus erythematosus
Authors: E Bodolay; Z Csiki; Z Szekanecz; T Ben; E Kiss; M Zeher; G Szücs; K Dankó; G Szegedi Journal: Clin Exp Rheumatol Date: 2003 May-Jun Impact factor: 4.473
Authors: Donato Alarcón-Segovia; Marta E Alarcón-Riquelme; Mario H Cardiel; Francisco Caeiro; Loreto Massardo; Antonio R Villa; Bernardo A Pons-Estel Journal: Arthritis Rheum Date: 2005-04
Authors: I Cavazzana; F Franceschini; N Belfiore; M Quinzanini; R Caporali; P Calzavara-Pinton; L Bettoni; A Brucato; R Cattaneo; C Montecucco Journal: Clin Exp Rheumatol Date: 2001 Jul-Aug Impact factor: 4.473
Authors: Christine G Parks; Glinda S Cooper; Leena A Nylander-French; Wayne T Sanderson; John M Dement; Philip L Cohen; Mary Anne Dooley; Edward L Treadwell; E William St Clair; Gary S Gilkeson; Jane A Hoppin; David A Savitz Journal: Arthritis Rheum Date: 2002-07
Authors: Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley Journal: N Engl J Med Date: 2003-10-16 Impact factor: 91.245
Authors: Melissa E Munroe; Kendra A Young; Joel M Guthridge; Diane L Kamen; Gary S Gilkeson; Michael H Weisman; Mariko L Ishimori; Daniel J Wallace; David R Karp; John B Harley; Jill M Norris; Judith A James Journal: Front Immunol Date: 2022-06-03 Impact factor: 8.786